Covifor

Covifor News

Cipla's remdevisir to cost Rs 4,000 per 100 mg vial in India; pricing among lowest globally: Report
science

Cipla's remdevisir to cost Rs 4,000 per 100 mg vial in India; pricing among lowest globally: Report

Cipla India business chief executive officer Nikhil Chopra said that the company was launching Cipremi commercially on Wednesday and aims to supply over 80,000 vials within the first month, but did not give details on pricing.

Covifor approved for COVID-19 treatment: Five important facts about generic drug priced at ₹5,400 per vial
Health

Covifor approved for COVID-19 treatment: Five important facts about generic drug priced at ₹5,400 per vial

Hetero, a Hyderabad-based pharmaceutical company, has launched its generic remdesivir drug, under the name Covifor, after approval from Drug Controller General of India on 21 June, 2020.

Hetero gets DCGI nod to launch anti-viral drug Remdesivir under brand name Covifor for COVID-19 treatment
India

Hetero gets DCGI nod to launch anti-viral drug Remdesivir under brand name Covifor for COVID-19 treatment

The drug has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease, the company said.